Skip to main content

Table 3 Bivariate and multivariate associations of number of lymph nodes harvested with 5-year and overall colon cancer-specific survival

From: Evaluation of lymph node numbers for adequate staging of Stage II and III colon cancer

 

Un-adjusted HRs (95% C.I.)

Adjusted a HRs (95% C.I.)

LNs extracted

Stage II

Stage III

Stage II

Stage III

5 Years DSS

    

Current guideline

    

< 12

ref

ref

ref

ref

≥ 12

0.65 (0.40, 1.07)

1.13 (0.77, 1.64)

0.61 (0.37, 1.00)

0.97 (0.64, 1.46)

Quartiles

    

1-6

ref

ref

ref

ref

7-11

0.93 (0.60, 1.43)

1.64 (0.91, 2.94)

0.85 (0.43, 1.67)

0.87 (0.41, 1.85)

12-19

0.89 (0.58, 1.34)

0.97 (0.55, 1.71)

0.68 (0.35, 1.32)

0.97 (0.55, 1.70)

≥ 20

0.54 (0.35, 0.83)

1.02 (0.57, 1.82)

0.42 (0.20, 0.90)

0.74 (0.39, 1.40)

Overall DSS

    

Current guideline

    

< 12

ref

ref

ref

ref

≥ 12

0.69 (0.44, 1.07)

1.09 (0.76, 1.56)

0.65 (0.42, 1.02)

0.95 (0.64, 1.40)

Quartiles

    

1-6

ref

ref

ref

ref

7-11

0.69 (0.37, 1.28)

0.84 (0.48, 1.48)

0.75 (0.40, 1.40)

0.83 (0.47, 1.47)

12-19

0.68 (0.38, 1.24)

1.01 (0.60, 1.70)

0.67 (0.37, 1.22)

0.94 (0.56, 1.59)

≥ 20

0.45 (0.23, 0.87)

0.94 (0.55, 1.61)

0.45 (0.23, 0.87)

0.69 (0.38, 1.26)

  1. DSS, disease-specific survival; HR, hazard ratio; CI, confidence interval.
  2. aAdjusted for age, race, and tumor grade. The Stage III model was also adjusted for chemotherapy status and the number of positive LNs.